Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCI

April 26, 2023

Medical

April 26, 2023 – Terumo today announced that its Ultimaster Nagomi™ drug-eluting coronary stent system has received certification under the European Union's Medical Device Regulation (MDR), alongside the launch of a large-scale post-market study evaluating the device's performance in complex percutaneous coronary intervention (PCI).

The Ultimaster Nagomi stent system is designed to offer enhanced deliverability and conformability, supporting interventional cardiologists in treating a wide range of coronary lesion complexities, including challenging anatomies.

The newly launched post-market study will generate real-world clinical data on the performance of the Ultimaster Nagomi system specifically in complex PCI procedures, further building the evidence base supporting its use.

"Achieving MDR certification and launching this large-scale study underscores our commitment to providing robust clinical evidence for the Ultimaster Nagomi system," said a Terumo representative. "We look forward to generating meaningful real-world data that will benefit both physicians and patients."

About Terumo India

Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo's starting point and unchanging corporate mission has been 'Contributing to Society through Healthcare'.

Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognized as one of India's Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India's healthcare system.

Media Contact

Terumo India Private Limited

About Terumo

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.